Clinical Trials Directory

Trials / Completed

CompletedNCT01274949

The Effect of Low Intensity Shockwave Therapy for ED in Post Radical Prostatectomy Patients Who Didn't Respond to PDE5i

The Effect of Low Intensity Shock Wave Therapy in Post Radical Prostatectomy Severe ED Patients Not Responding to Oral Medication

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
Male
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Low Intensity Shock Wave Therapy (LI-ESWT) was shown to have a beneficial effect on ED patients responding to PDE5i's. This study aimed to determine the capability of LI-ESWT to affect patients who underwent radical prostatectomy who did not respond to PDE5 inhibitor therapy.

Detailed description

We included severe ED patients that underwent radical prostatectomy at least one year previously and failed to respond to PDE5i therapy, who scored 0-2 on the rigidity scale (RS) during PDE5i therapy. Treatment included 2 sessions/week for 3 weeks, repeated after a 3-week no-treatment interval. At each session LI-ESWT was applied on the penile shaft and crus for 3 minutes in 5 different penile anatomical sites (intensity of 0.09 mj/mm2, 300 shocks/site). One-month after end of treatment the same baseline assessment was repeated. An active PDE5i medication regime was then provided and final erectile function was reassessed. Main endpoints for success were changes in RS and in the International Index of Erectile Function (IIEF-ED) Domain score. This study further emphasises the need to study specific populations with unique etiologies causing ED.

Conditions

Interventions

TypeNameDescription
DEVICELI-ESWTLow intensity shock wave treatment - 12 sessions

Timeline

Start date
2010-02-01
Primary completion
2011-07-01
Completion
2011-08-01
First posted
2011-01-12
Last updated
2011-09-14

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01274949. Inclusion in this directory is not an endorsement.